Metformin in High Metabolic Risk Pregnancies - A Patient-Level Meta-Analysis.
Aya Mousa, Tone S Løvvik, Sven M Carlsen et al.
✦ AI-curated · Sources linked
In 30 seconds
This patient-level meta-analysis evaluated the effects of metformin on gestational diabetes (GDM) and pregnancy outcomes in 2,485 pregnant individuals without diabetes. The study found that metformin did not significantly reduce GDM rates (adjusted odds ratio 1.00; 95% CI 0.71 to 1.41) but was associated with longer gestation (mean difference 0.30 weeks; 95% CI 0.06 to 0.54) and lower odds of preterm birth (adjusted odds ratio 0.64; 95% CI 0.47 to 0.89).
Key findings
- Metformin did not reduce GDM rates (adjusted odds ratio 1.00; 95% CI 0.71 to 1.41).
- Associated with longer gestation by 0.30 weeks (95% CI 0.06 to 0.54).
- Lower odds of preterm birth (adjusted odds ratio 0.64; 95% CI 0.47 to 0.89).
- Gastrointestinal side effects were more common with metformin.
Why it matters
Understanding the effects of metformin in high metabolic risk pregnancies is crucial for managing potential GDM and optimizing pregnancy outcomes. This study provides insights into the drug's efficacy and safety profile, informing clinical decision-making.